ATYR PHARMA, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.57 USD | -1.57% |
|
-1.88% | +11.35% |
| Mar. 15 | RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier | MT |
| Mar. 14 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 16.22 | 39.52 | 207.6 | 63.53 | 82.57 | 106.7 | - | - |
| Enterprise Value (EV) 1 | 16.22 | 39.52 | 207.6 | 63.53 | 82.57 | 106.7 | 106.7 | 106.7 |
| P/E ratio | -0.59 x | -2.19 x | -4.22 x | -1.37 x | -1.5 x | -1.58 x | -1.64 x | -17.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 38.4 x | 3.78 x | - | 6.12 x | 234 x | 40.6 x | 11.5 x | 1.15 x |
| EV / Revenue | 38.4 x | 3.78 x | - | 6.12 x | 234 x | 40.6 x | 11.5 x | 1.15 x |
| EV / EBITDA | -0.73 x | -2.58 x | -6.19 x | -1.38 x | - | -1.49 x | -1.45 x | 2.12 x |
| EV / FCF | -785,991 x | -2,806,987 x | -6,240,309 x | - | - | - | - | - |
| FCF Yield | -0% | -0% | -0% | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 3,890 | 10,185 | 27,791 | 29,009 | 58,560 | 67,941 | - | - |
| Reference price 2 | 4.170 | 3.880 | 7.470 | 2.190 | 1.410 | 1.570 | 1.570 | 1.570 |
| Announcement Date | 3/26/20 | 3/23/21 | 3/14/22 | 3/9/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.422 | 10.46 | - | 10.39 | 0.353 | 2.625 | 9.257 | 92.82 |
| EBITDA 1 | -22.34 | -15.34 | -33.54 | -46.17 | - | -71.7 | -73.4 | 50.4 |
| EBIT 1 | -22.98 | -15.91 | -34.02 | -46.4 | -54.92 | -66.16 | -67.98 | -8.903 |
| Operating Margin | -5,445.02% | -152.19% | - | -446.79% | -15,557.79% | -2,520.53% | -734.39% | -9.59% |
| Earnings before Tax (EBT) 1 | -23.76 | -16.23 | -33.78 | -45.34 | -50.4 | -63.29 | -66.67 | -7.568 |
| Net income 1 | -23.6 | -16.22 | -33.77 | -45.34 | -50.39 | -63.29 | -66.66 | -7.711 |
| Net margin | -5,593.13% | -155.18% | - | -436.53% | -14,274.5% | -2,411.01% | -720.16% | -8.31% |
| EPS 2 | -7.030 | -1.770 | -1.770 | -1.600 | -0.9400 | -0.9925 | -0.9550 | -0.0875 |
| Free Cash Flow | -20.64 | -14.08 | -33.27 | - | - | - | - | - |
| FCF margin | -4,890.76% | -134.66% | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/23/21 | 3/14/22 | 3/9/23 | 3/14/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 8.25 | - | - | - | - | - | 10.39 | - | - | 0.353 | - | 0.0275 | 0.03 | 2.532 | 0.035 | - |
| EBITDA 1 | -4.15 | -7.605 | -8.532 | -12.3 | -12.52 | -13.49 | -7.911 | -12.71 | -13.4 | -12.44 | - | -16.8 | -17.5 | -18.3 | -19.2 | - |
| EBIT 1 | - | -7.728 | -8.64 | -12.38 | -12.58 | -13.49 | -7.95 | -12.79 | -13.56 | -12.62 | -15.96 | -16.17 | -16.69 | -13.81 | -17.65 | -17.26 |
| Operating Margin | - | - | - | - | - | - | -76.55% | - | - | -3,573.65% | - | -58,795.16% | -55,624.43% | -545.46% | -50,422.86% | - |
| Earnings before Tax (EBT) 1 | -4.7 | -7.669 | -8.561 | -12.15 | -12.42 | -13.24 | -7.523 | -11.95 | -12.34 | -11.34 | -14.76 | -15.63 | -16.2 | -14.22 | -17.27 | -17.26 |
| Net income 1 | -4.69 | -7.667 | -8.559 | -12.15 | -12.42 | -13.24 | -7.521 | -11.95 | -12.34 | -11.34 | -14.76 | -15.63 | -16.2 | -14.22 | -17.27 | -17.26 |
| Net margin | -56.85% | - | - | - | - | - | -72.41% | - | - | -3,212.46% | - | -56,845.45% | -53,991.67% | -561.34% | -49,335% | - |
| EPS 2 | -0.5800 | -0.4200 | -0.3100 | -0.4400 | -0.4400 | -0.4600 | -0.2600 | -0.2900 | -0.2200 | -0.2000 | -0.2500 | -0.2500 | -0.2575 | -0.2225 | -0.2675 | -0.2500 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/13/20 | 11/10/21 | 3/14/22 | 5/9/22 | 8/15/22 | 11/10/22 | 3/9/23 | 5/9/23 | 8/9/23 | 11/9/23 | 3/14/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | -20.6 | -14.1 | -33.3 | - | - | - | - | - |
| ROE (net income / shareholders' equity) | -86.1% | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | 0.08 | - | 0.19 | - | - | - | - | - |
| Capex / Sales | 18.72% | - | - | - | - | - | - | - |
| Announcement Date | 3/26/20 | 3/23/21 | 3/14/22 | 3/9/23 | 3/14/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.57
USD
Average target price
25.25
USD
Spread / Average Target
+1,508.28%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.35% | 107M | |
| +1.51% | 42.75B | |
| +8.57% | 41.34B | |
| +49.22% | 41.61B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- LIFE Stock
- Financials aTyr Pharma, Inc.
